Evidence-Based Complementary and Alternative Medicine / 2012 / Article / Fig 2

Research Article

NBM-HD-1: A Novel Histone Deacetylase Inhibitor with Anticancer Activity

Figure 2

Determination of the inhibition of total HDAC activity by NBM-HD-1. (a) C6 cells ( ) were seeded in 60 mm dishes and incubated for 14 h then treated with various concentrations (4.3–17.0 μM) of NBM-HD-1 and SB (4.0 mM, as a positive control) for 48 h, and then the nuclear fraction protein was isolated to determine the inhibition of total HDAC enzyme activity. Data are shown as the mean ± SD. * ; *** versus the control. C6 and MCF-7 cells were cultured in six-well culture plates ( /well) and treated with NBM-HD-1 (at a fixed concentration of 17.0 μM), SAHA (5.0 μM), or SB (4.0 mM) for 24 h. Immunostaining was used to evaluate biomarkers of HDACis such as Ac-histone 3 and gelsolin after cells were treated with HDACis. (b) Ac-histone 3 and (c) gelsolin protein levels were determined by confocal microscopy. All these tests were performed in three independent experiments. A representative experiment of the three replicates is shown.
781417.fig.002a
(a)
781417.fig.002b
(b)
781417.fig.002c
(c)

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.